M23-991: Open-Label PET Study to Evaluate Dopamine Receptor occupancy after doses of ABBV-932

• Research type

  Research Study

• Full title

  An Open-Label Positron Emission Tomography (PET) Study to Evaluate the Dopamine D2 and D3 Receptor Occupancy in the Brain after Multiple Doses of ABBV-932

• IRAS ID

  1009506

• Contact name

  Alice Butler

• Contact email

  uk.reg.csm.cta@abbvie.com

• Sponsor organisation

  AbbVie Deutschland GmbH & Co. KG

• Clinicaltrials.gov Identifier

  NCT06300580

• Research summary

  The main objective of this study is to evaluate the dopamine D2 and D3 receptor occupancy in the brain as measured by PET with radiotracer [11C]-(+)-PHNO up to 14 days of once-daily oral doses of ABBV-932 in healthy subjects.
  ABBV-932 is a prodrug of DCAR (desmethyl-cariprazine), which is a dopamine D3 receptor-preferring D3/D2 receptor partial agonist. Approximately 12 adult healthy volunteers will be enrolled in the United Kingdom.
  Participants will receive ABBV-932 oral capsules once daily for 2 weeks and followed for 60 days.

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  24/LO/0452

• Date of REC Opinion

  8 Aug 2024

• REC opinion

  Further Information Favourable Opinion